SNSE - Sensei Biotherapeutics reprioritizes pipeline programs provides cash runway update

Sensei Biotherapeutics (SNSE) says that it is reprioritizing its pipeline programs to focus on its product candidates.With the reallocation of resources, Sensei expects its cash and cash equivalents will be sufficient to fund its operations into the first half of 2024.The reprioritizing includes its multi-antigenic next generation ImmunoPhage candidate, SNS-401-NG, and its monoclonal antibody SNS-VISTA (V-set Immunoglobulin Domain Suppressor of T cell Activation) candidate.The company also highlighted the discontinuation of its single-antigen phage SNS-301 program upon analysis of clinical activity and antigen specific T-cell data.Shares down nearly 1% post market.

For further details see:

Sensei Biotherapeutics reprioritizes pipeline programs, provides cash runway update